ONE-WAYDated event · through FY2026

Termination of the sales agreement with KAKEN PHARMACEUTICAL CO.,LTD. for an improved fenofibrate formulation

This covers the specific event in which the sales rights license agreement with KAKEN PHARMACEUTICAL CO.,LTD. for an improved fenofibrate formulation ended by December 2025. It concerns a theme tied to a specific product, counterparty and termination of a sales rights license agreement.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2026 →Last written FY2026

Directionhurts0 helps · 1 hurts · 0 flat